PT - JOURNAL ARTICLE AU - Gastine, Silke AU - Pang, Juanita AU - Boshier, Florencia A.T. AU - Carter, Simon J. AU - Lonsdale, Dagan O. AU - Cortina-Borja, Mario AU - Hung, Ivan F.N. AU - Breuer, Judy AU - Kloprogge, Frank AU - Standing, Joseph F. TI - Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies AID - 10.1101/2020.08.20.20178699 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.20.20178699 4099 - http://medrxiv.org/content/early/2020/08/23/2020.08.20.20178699.short 4100 - http://medrxiv.org/content/early/2020/08/23/2020.08.20.20178699.full AB - Background SARS-CoV-2 viral loads change rapidly following symptom onset so to assess antivirals it is important to understand the natural history and patient factors influencing this. We undertook an individual patient-level meta-analysis of SARS-CoV-2 viral dynamics in humans to describe viral dynamics and estimate the effects of antivirals used to-date.Methods This systematic review identified case reports, case series and clinical trial data from publications between 1/1/2020 and 31/5/2020 following PRISMA guidelines. A multivariable Cox proportional hazards regression model (Cox-PH) of time to viral clearance was fitted to respiratory and stool samples. A simplified four parameter nonlinear mixed-effects (NLME) model was fitted to viral load trajectories in all sampling sites and covariate modelling of respiratory viral dynamics was performed to quantify time dependent drug effects.Findings Patient-level data from 645 individuals (age 1 month-100 years) with 6316 viral loads were extracted. Model-based simulations of viral load trajectories in samples from the upper and lower respiratory tract, stool, blood, urine, ocular secretions and breast milk were generated. Cox-PH modelling showed longer time to viral clearance in older patients, males and those with more severe disease. Remdesivir was associated with faster viral clearance (adjusted hazard ratio (AHR) = 9·19, p< 0·001), as well as interferon, particularly when combined with ribavirin (AHR = 2·2, p = 0·015; AHR = 6·04, p = 0·006).Interpretation Combination therapy including interferons should be further investigated. A NLME model for designing and analysing viral pharmacodynamics in trials has been established.Evidence before this study We performed a systematic literature search for studies reporting serial viral load measurements in humans for SARS-CoV-2 in MEDLINE and Embase, MedRxiv and BioRxiv along with the PROSPERO systematic review register. As of 27/5/20, no previous or ongoing review has systematically searched for and pooled individual patient-level serial viral load data in this disease or depicted SARS-CoV-2 viral load trajectories in a meta-analysis. In addition, modelling of SARS-CoV-2 viral dynamics and model-based quantification and simulation of antiviral drug activity is to date only available from single studies. A comprehensive dataset for distinguishing between natural history of the disease and drug effect related viral load decline was therefore lacking.Added value of this study This individual patient meta-analysis includes a large dataset of individual patient serial viral load measurements for SARS-CoV-2 with and without drug therapy. The full dataset contains 645 individuals with 6316 viral load samples. The majority were sampled from the upper respiratory tract. There were also samples available from the lower respiratory tract, blood, urine and stool, breast milk and ocular secretions. This enabled us to estimate parameters of a nonlinear mixed effects (NLME) viral dynamics model to characterise the course of viral shedding across each sample site.A multivariable Cox proportional hazards regression analysis revealed increasing age, disease severity and male sex to be associated with longer time to viral clearance, indicating that patients with worse clinical outcomes do have higher viral loads. A NLME model incorporating drug effects showed early initiation of antivirals shortened time to viral clearance. By including data on multiple drug combinations Cox proportional hazards suggests type I interferons plus ribavirin to be potentially synergistic in vivo. Our NLME model can be used to determine the sample size of future Phase II trials. For example, to detect a significant difference in proportion of patients clearing the virus after 7 days of treatment in patients starting therapy at day 3 post symptom onset with 90% power, one would require 606, 284, 90 or 31 patients per group for lopinavir/ritonavir, ribavirin, interferon or interferon plus ribavirin drug effects respectively. The later that antivirals are initiated, the smaller the drug effect and hence the larger sample size required to determine antiviral activity.Implications of all the available evidence This individual patient level meta-analysis provides insight into the natural history of the SARS-CoV-2 viral dynamics through the biggest serial viral load data set available to date. A NLME viral dynamics model was established enabling estimation of the impact of drug effects on viral clearance. The full data set and model code is available to as a tool to design and analyse Phase II antiviral trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo specific funding was available for this work. Support at institution level came from the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London, and J.F.S. and F.K. were supported by United Kingdom Medical Research Council (MRC) Fellowships (grants M008665 and P014534). JB receives funding from the NIHR UCL/UCLH Biomedical Research Centre. JP is supported by a Rosetrees Trust PhD fellowship (M876). FTB is supported by a Wellcome Trust Collaborative Award (203268) to JB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:review/ meta-analysis no approval neededAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe final dataset is available at github https://github.com/ucl-pharmacometrics/SARS-CoV-2-viral-dynamic-meta-analysis